Shares of a mid-cap pharmaceutical firm recorded strong buying interest during the fag-end trading session on Wednesday. The company is Eris Lifesciences Ltd and the stock settled 11.04 per cent higher at Rs 1,484.95.
The strong uptick came after the company reported a stellar 200.10 per cent year-on-year (YoY) jump in its March 2026 quarter (Q4 FY26) consolidated net profit.
During the period under review, profit stood at Rs 281.61 crore compared to Rs 93.84 crore in the corresponding quarter last year. The sharp jump in profitability was primarily driven by a deferred tax gain of Rs 132.18 crore during the quarter, compared to a deferred tax gain of Rs 4.87 crore in the year-ago period.
The company's revenue rose 7 per cent to Rs 757 crore in Q4 FY26 from Rs 705 crore a year ago.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) increased 8 per cent YoY to Rs 274 crore from Rs 252 crore, while EBITDA margin improved marginally to 36.2 per cent from 35.8 per cent a year ago.
Alongside the results, the company's Board also cleared an interim dividend payment of Rs 7.21 per share, translating into a payout of 721 per cent, for FY27.
"Declaration of interim dividend of Rs 7.21/- (at the rate of 721 per cent) on each fully paid-up equity share of Re 1/- each for the Financial Year 2026-2027," it stated.
Record date
The company has fixed May 29, 2026, as the record date for dividend payout.
"The record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as Friday, May 29, 2026. The payment of the interim dividend would be made to the eligible shareholders on or before June 19, 2026," Eris said.
The pharmaceutical stock making waves with these massive headline numbers is the mid-cap firm Eris Lifesciences Ltd.
Following the announcement of its blockbuster fourth-quarter (Q4 FY26) financial results, buying interest surged during the final hours of trading, pushing the stock up 11.04% to close at ₹1,484.95 on the National Stock Exchange (NSE).
Here are the key operational and financial details driving this market rally.
1. Q4 FY26 Financial Performance Overview
Eris Lifesciences reported stellar growth across its key bottom-line metrics, largely amplified by a substantial accounting adjustment.
| Financial Metric | Q4 FY26 (Jan–Mar 2026) | Q4 FY25 (Jan–Mar 2025) | Year-on-Year (YoY) Change |
| Consolidated Net Profit | ₹281.61 crore | ₹93.84 crore | +200.10% |
| Revenue from Operations | ₹757 crore | ₹705 crore | +7.00% |
| EBITDA | ₹274 crore | ₹252 crore | +8.00% |
| EBITDA Margin | 36.2% | 35.8% | +40 bps |
The Profit Driver: While core operational revenue grew at a steady 7%, the spectacular 200% surge in net profit was primarily driven by a massive deferred tax gain of ₹132.18 crore recognized during the quarter, compared to just ₹4.87 crore in the same period last year.
2. The 721% Dividend Details
Alongside the corporate earnings, the Board of Directors approved a highly lucrative interim dividend payout.
Dividend Rate: 721% per equity share. Because the face value of each fully paid-up Eris Lifesciences share is ₹1, this translates to an interim dividend of ₹7.21 per share.
Applicable Period: This interim dividend has been declared for the ongoing financial year 2026–2027 (FY27).
Important Dates:
Record Date: Fixed for Friday, May 29, 2026. This is the cutoff date to determine which shareholders are officially eligible to receive the payout.
Payment Timeline: Eligible shareholders will receive the dividend credit directly into their bank accounts on or before June 19, 2026.
No comments:
Post a Comment